Cost-Effectiveness of Brentuximab Vedotin Versus Physician’s Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada

INTRODUCTION: Brentuximab vedotin versus physician’s choice of methotrexate (MTX) or bexarotene (BEX) significantly improved progression-free survival (PFS) (median PFS, 16.7 vs. 3.5 months) and delayed time to subsequent treatment (8.4 vs. 3.7 months), with similar overall survival in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsea, David, Savage, Kerry J., Lilley, Cameron, Lisano, Julie, Liu, Jingmin, Yu, Kristina S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129955/
https://www.ncbi.nlm.nih.gov/pubmed/36920744
http://dx.doi.org/10.1007/s12325-023-02470-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129955/
https://www.ncbi.nlm.nih.gov/pubmed/36920744
http://dx.doi.org/10.1007/s12325-023-02470-9

Ejemplares similares